IXING Biotechnology secures Series B round, raises tens of millions of yuan

IXING Biotechnology has recently received tens of millions of yuan in Series B financing round from Yushan Capital. Earlier, the company had obtained early investment from industry funds and industrial capitals such as ZY Bio, ShiFeng Medical Instrument, and Yuansheng Venture Capital etc.

IXING Biotechnology has recently received tens of millions of yuan in Series B financing round from Yushan Capital. Earlier, the company had obtained early investment from industry funds and industrial capitals such as ZY Bio, ShiFeng Medical Instrument, and Yuansheng Venture Capital etc.

After this round of financing, IXING Biotechnology will expand its POCT product capacity and bolster market promotion.

Established in April 2013, IXING Biotechnology is a developer of intelligent real-time diagnostic technologies intended for various medical uses. The company’s intelligent diagnostic technologies is based on the company’s point-of-care testing (POCT) platform that covers new drug research and development, medical devices development, precision medicine and medical health services, providing clinical assistant with decision-making, disease prediction models, clinical trial analysis and personalized treatment services.

The company has already obtained 12 product registration certificates from the National Medical Products Administration of China, and the products cover heart markers, inflammation markers, stomach function, kidney function and other fields.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/26/ixing-biotechnology-secures-series-b-round-raises-tens-of-millions-of-yuan/.

Leave a Reply

Please Login to Comment